Komori
Rohto Pharmaceutical (4527) · RiskRestated

Risk of termination of partnerships with other companies

First written in FY2016. 19 of 20 entries say "Restated". Latest entry: FY2024-Q3.

20entries
9years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2024-Q32016: 120162017: 320172018: 320182019: 320192020: 320202021: 220212022: 220222023: 220232024: 1
Same theme, other companies
Reliance on External Partners, Including Licensors, Sales Partners and CROsA theme 111 companies write about · 114 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2020: 9 of 47 companies on the "Worse" side.

54 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 111 companies compared. The sentences above are computed from all 111.
Full recordFilings, disclosures and news, newest first
  1. FY2024-Q3RestatedAnnual report

    「During the cumulative third quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    It is stated that there has been no material change regarding the risk of termination of partnerships with other companies.
  2. FY2024-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    It is stated that there has been no material change regarding the risk of termination of partnerships with other companies.
  3. FY2024-Q1RestatedAnnual report

    「During the cumulative first quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    It is stated that there has been no material change regarding the risk of termination of partnerships with other companies.
  4. FY2023-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    It is stated that there has been no material change regarding the risk of termination of partnerships with other companies.
  5. FY2023-Q1RestatedAnnual report

    「During the cumulative first quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    It is stated that there has been no material change regarding the risk of termination of partnerships with other companies.
  6. FY2022-Q1RestatedAnnual report

    「During the cumulative first quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    It is stated that there has been no material change from the previous year's disclosure regarding the risk of termination of partnerships with other companies.
  7. FY2021-Q3RestatedAnnual report

    「During the cumulative third quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    It is stated that there has been no material change regarding the risk of termination of partnerships with other companies.
  8. FY2021-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    It is stated that there has been no material change from the previous year's disclosure regarding the risk of termination of partnerships with other companies.
  9. FY2021-Q1RestatedAnnual report

    「During the cumulative first quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    It is stated that there has been no material change from the previous year's disclosure regarding the risk of termination of partnerships with other companies.
  10. FY2020-Q3RestatedAnnual report

    「During the cumulative third quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    It is stated that there has been no material change from the previous year's disclosure regarding the risk of termination of partnerships with other companies.
  11. FY2020-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    It is stated that there has been no material change from the previous year's disclosure regarding the risk of termination of partnerships with other companies.
  12. FY2020-Q1RestatedAnnual report

    「During the cumulative first quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    It is stated that there has been no material change from the previous year's disclosure regarding the risk of termination of partnerships with other companies.
  13. FY2019-Q3RestatedAnnual report

    「During the cumulative third quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    It is stated that there has been no material change from the previous year's disclosure regarding the risk of termination of partnerships with other companies.
  14. FY2019-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    It is stated that there has been no material change from the previous year's disclosure regarding the risk of termination of partnerships with other companies.
  15. FY2019-Q1RestatedAnnual report

    「During the cumulative first quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    It is stated that there has been no material change from the previous year's disclosure regarding the risk of termination of partnerships with other companies.
  16. FY2018-Q3RestatedAnnual report

    「During the cumulative third quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    It is stated that there has been no material change from the previous year's disclosure regarding the risk of termination of partnerships with other companies.
  17. FY2018-Q2RestatedAnnual report

    「During the cumulative second quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    It is stated that there has been no material change from the previous year's disclosure regarding the risk of termination of partnerships with other companies.
  18. FY2018-Q1RestatedAnnual report

    「During the cumulative first quarter under review, there were no material changes in unusual fluctuations in the Company's financial position, operating results or cash flows, or in the business and other risks described in the annual securities report for the previous fiscal year.」

    It is stated that there has been no material change from the previous year's disclosure regarding the risk of termination of partnerships with other companies.
  19. FY2017RestatedAnnual report

    「The Group enters into alliances with other companies in various forms, including joint development, joint sales and product introductions, including manufacturing and sales under license agreements. If these alliances are terminated for any reason, operating performance and financial condition could be affected.」

    It reaffirms the risk of terminating alliances involving joint development, joint sales and licensing.
  20. FY2016First statedAnnual report

    「The Group enters into alliances with other companies in various forms, including joint development, joint sales and product introductions, including manufacturing and sales under license agreements. If these alliances are terminated for any reason, operating performance and financial condition could be affected.」

    The termination of partnerships in various forms, including joint development, joint sales and product introductions involving licensing, is identified as a risk.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Rohto Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.